Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AMDL, Inc.
AMDL responds to American Stock Exchange on continued listing standards
June 23rd, 2006
AMDL, Inc., (ADL) developer and marketer of tests for the early detection of cancer and other serious diseases, reported that it has submitted to the American Stock Exchange (AMEX) a plan that brings the company into compliance with the AMEX Company Continued Listing Standards. Highlights of an overview letter sent by Gary L. Dreher, CEO, to the AMEX include: * The recently announced planned acquisition of Jade Pharmaceutical, Inc., and its two Chinese subsidiaries will increase AMDL's net worth by an unaudited pro forma basis as of December 31, 2005 of $6,186,582. AMEX had said that AMDL did not meet the $4,000,000 stockholders' equity requirement...
Source: Biotech Law Weekly (2006-06-23)
|
